![]() ![]() ![]() Polyester alone makes up 60% of the $2.5 trillion fashion industry and is the biggest blocker preventing brands from meeting sustainability mandates. Our platform technology, AesculaGel offers adaptive response to a wide range of stimuli and can be tailor-made for biocompatibility, material strength, and a range of other attributes.ĪLT TEX is a Toronto-based biomaterials startup that has developed the world’s first biodegradable and carbon neutral fabric, engineered from the world’s largest landfill contributor - food waste. We design custom smart materials for a range of biomedical, commercial, and industrial applications. In short, Y-Combinator was only the beginning.ĪesculaTech believes in building better lives through smart chemistry. AesculaTech was named a Rosenman Innovator, received a National Science Foundation I-Corps grant, was a finalist in the 2019 Octane High Tech Awards, and is a graduate of both the Y Combinator and TMCx accelerator programs. In coordination with partners across several sectors, we have a variety of groundbreaking technologies in the works that live up to our vision. Though Humidifeye is not yet FDA approved, expect to hear about it soon! In contrast to existing technologies, our product will not extrude, or cause discomfort as it adapts to patients. ![]() Our thermally responsive, form-fitting materials are suitable for sustained yet reversible occlusion across a range of treatment times. Dry eye affects more than 25 million Americans and the global treatment market is projected higher than $6 Billion within the next decade. Our cornerstone product, Humidifeye, is an ophthalmic platform to treat dry eye disease. Our platform technology, AesculaGel offers adaptive response to a wide range of stimuli and can be tailor-made for biocompatibility, material strength, and a range of other attributes.įounded by one of MIT's 35 under 35 Innovators, AesculaTech is the shared vision of scientists, engineers, and medical experts. If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at believes in building better lives through smart chemistry. By teaching our body’s immune system to recognize and kill the mutations that cause cancer, we can eliminate the majority of all cancer deaths. If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at makes cancer vaccines. Our team is led by our Chief Executive Officer, Jen Herbach, who has more than a decade of biotech industry experience including with Amunix (the second largest oncology pre-clinical stage acquisition). Mark Yarchoan (principal investigator of multiple cancer vaccine clinical trials). Liz Jaffee (Chair of President Biden’s Cancer Advisory Panel) and our Chief Medical Officer, Dr. Our team includes some of the leading cancer vaccine experts in the world including: our Chief Scientific Officer, Dr. In the long run, we envision a world where every adult receives our vaccines annually – preventing the majority of cancer deaths. Our first product is a vaccine for the treatment of lung cancer that targets the KRAS mutation, the most common mutation in cancer, accounting for about 25-30% of all cancer deaths. The immune system usually doesn’t recognize these mutations, but our technology platform enables us to train the immune system to recognize and attack these cancers. Surprisingly, a small number of these mutations account for the vast majority of cancer deaths. By teaching our body’s immune system to recognize and kill the mutations that cause cancer, we can eliminate the majority of all cancer deaths.Ī little more detail to understand our scientific approach: A normal cell turns into cancer when it develops a mutation that makes it grow aggressively. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |